Indantadol

Indantadol
(IUPAC) ime
	N-(2,3-dihidro-1H-inden-2-il)glicinamid
Klinički podaci
Identifikatori
CAS broj	202844-10-8
ATC kod	nije dodeljen
ChemSpider	16017060
UNII	Z3867B9SQP
Hemijski podaci
Formula	C11H14N2O
Mol. masa	190,24 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C11H14N2O/c12-7-11(14)13-10-5-8-3-1-2-4-9(8)6-10/h1-4,10H,5-7,12H2,(H,13,14); Key: UWPTYLJSWCCUFZ-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Nije kontrolisana supstanca
Način primene	Oralno

Indantadol (CHF-3381, V-3381) je lek koje je izučavan za moguću primenu kao antikonvulsant i neuroprotectiv, i koji se razvija kao potencijalni tretman neuropatičkog bola i hroničnog kašlja u Evropi.^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9] On takođe deluje kao kompetitivni, reverzibilni, i neselektivni inhibitor monoaminske oksidaze,^[6]^[7]^[10] i kao nekompetitivni antagonist NMDA receptora niskog afiniteta.^[2]^[3]^[11]

Reference

↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ ^2,0 ^2,1 Villetti G, Bregola G, Bassani F, et al. (June 2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866–78. DOI:10.1016/S0028-3908(01)00026-0. PMID 11378157.
↑ ^3,0 ^3,1 Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157–66. DOI:10.1016/S0091-3057(01)00591-3. PMID 11566153.
↑ Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071–4. DOI:10.1097/00001756-200211150-00016. PMID 12438928.
↑ Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. DOI:10.1124/jpet.103.050039. PMID 12750440.
↑ ^6,0 ^6,1 „CHF 3381”. Drugs in R&D 5 (1): 28–30. 2004. PMID 14725488.
↑ ^7,0 ^7,1 Mattia C, Coluzzi F (September 2007). „Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”. IDrugs : the Investigational Drugs Journal 10 (9): 636–44. PMID 17786847.
↑ „IN-STEP Phase IIb study results”. Arhivirano iz originala na datum 2014-08-13.
↑ „Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. Arhivirano iz originala na datum 2014-08-13.
↑ Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565–74. DOI:10.1016/j.jpain.2006.02.004. PMID 16885013.
↑ Barbieri M, Bregola G, Buzzi A, et al. (August 2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333–41. DOI:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

Povezano

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[pmid11378157-2] 2,0 ^2,1 Villetti G, Bregola G, Bassani F, et al. (June 2001). „Preclinical evaluation of CHF3381 as a novel antiepileptic agent”. Neuropharmacology 40 (7): 866–78. DOI:10.1016/S0028-3908(01)00026-0. PMID 11378157.

[pmid11566153-3] 3,0 ^3,1 Gandolfi O, Bonfante V, Voltattorni M, et al. (September 2001). „Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms”. Pharmacology, Biochemistry, and Behavior 70 (1): 157–66. DOI:10.1016/S0091-3057(01)00591-3. PMID 11566153.

[pmid12438928-4] Zucchini S, Buzzi A, Bergamaschi M, Pietra C, Villetti G, Simonato M (November 2002). „Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist”. Neuroreport 13 (16): 2071–4. DOI:10.1097/00001756-200211150-00016. PMID 12438928.

[pmid12750440-5] Villetti G, Bergamaschi M, Bassani F, et al. (August 2003). „Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 804–14. DOI:10.1124/jpet.103.050039. PMID 12750440.

[pmid14725488-6] 6,0 ^6,1 „CHF 3381”. Drugs in R&D 5 (1): 28–30. 2004. PMID 14725488.

[pmid17786847-7] 7,0 ^7,1 Mattia C, Coluzzi F (September 2007). „Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain”. IDrugs : the Investigational Drugs Journal 10 (9): 636–44. PMID 17786847.

[urlIN-STEP_Phase_IIb_study_results-8] „IN-STEP Phase IIb study results”. Arhivirano iz originala na datum 2014-08-13.

[urlVernalis_initiates_Pilot_Study_of_V3381_in_patients_with_chronic_cough-9] „Vernalis initiates Pilot Study of V3381 in patients with chronic cough”. Arhivirano iz originala na datum 2014-08-13.

[pmid16885013-10] Mathiesen O, Imbimbo BP, Hilsted KL, Fabbri L, Dahl JB (August 2006). „CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model”. The Journal of Pain 7 (8): 565–74. DOI:10.1016/j.jpain.2006.02.004. PMID 16885013.

[pmid12890713-11] Barbieri M, Bregola G, Buzzi A, et al. (August 2003). „Mechanisms of action of CHF3381 in the forebrain”. British Journal of Pharmacology 139 (7): 1333–41. DOI:10.1038/sj.bjp.0705381. PMC 1573965. PMID 12890713.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]